Axovant Sciences (AXON) Earning Somewhat Positive Media Coverage, Report Finds

Media stories about Axovant Sciences (NASDAQ:AXON) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Axovant Sciences earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.1908103715988 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

Shares of Axovant Sciences (NASDAQ:AXON) traded down $0.15 on Monday, reaching $5.30. 3,276,100 shares of the company’s stock were exchanged, compared to its average volume of 1,025,770. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences has a twelve month low of $4.60 and a twelve month high of $27.98.

AXON has been the subject of several research analyst reports. Oppenheimer reiterated a “buy” rating and set a $30.00 price target on shares of Axovant Sciences in a report on Monday, September 25th. Jefferies Group set a $40.00 price target on shares of Axovant Sciences and gave the stock a “buy” rating in a report on Friday, August 25th. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Axovant Sciences in a research note on Wednesday, September 27th. BidaskClub raised shares of Axovant Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 5th. Finally, Robert W. Baird reissued a “hold” rating and issued a $6.00 price objective on shares of Axovant Sciences in a research note on Wednesday, November 1st. Four analysts have rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $14.13.

WARNING: “Axovant Sciences (AXON) Earning Somewhat Positive Media Coverage, Report Finds” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2017/12/18/axovant-sciences-axon-earning-somewhat-positive-media-coverage-report-finds.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply